Alterity Therapeutics (ATHE) Total Non-Current Liabilities (2009 - 2025)
Alterity Therapeutics (ATHE) posted quarterly Total Non-Current Liabilities of $42980.1 for Q4 2025, up 52.43% year-over-year from $28197.3 in Q4 2024, and down 24.21% quarter-over-quarter from $56707.2 in Q2 2025.
Alterity Therapeutics (ATHE) Total Non-Current Liabilities (2009 - 2025) Analysis & Trends
Alterity Therapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $42980.1 for Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 52.43% year-over-year to $42980.1; the TTM figure through Dec 2025 stood at $42980.1 (up 52.43% YoY), while the FY2025 annual figure was $56707.2, up 65.75% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $42980.1, down from $56707.2 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $56707.2 in Q2 2025, with the low at -$1.2 million in Q2 2024.
- The 5-year median for Total Non-Current Liabilities is $33909.0 (2022), against an average of -$82282.5.
- The sharpest annual moves came in 2021 and 2024: Total Non-Current Liabilities surged 388.34% in 2021, then tumbled 93911.18% in 2024.
- Alterity Therapeutics' Total Non-Current Liabilities stood at $28873.4 in 2021, then advanced by 7.74% to $31108.7 in 2022, then surged by 60.1% to $49804.0 in 2023, then plunged by 43.38% to $28197.3 in 2024, then soared by 52.43% to $42980.1 in 2025.
- Business Quant data shows ATHE's Total Non-Current Liabilities at $42980.1 in Q4 2025, $56707.2 in Q2 2025, and $28197.3 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Alterity Therapeutics | 48.56 Mn | 16.26 Mn | - | 42,980.09 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 42,980.09 |
| Jun 30, 2025 | 56,707.16 |
| Dec 31, 2024 | 28,197.30 |
| Jun 30, 2024 | -1.15 Mn |
| Dec 31, 2023 | 49,804.03 |
| Jun 30, 2023 | 1,227.10 |
| Dec 31, 2022 | 31,108.67 |
| Jun 30, 2022 | 52,724.51 |
| Dec 31, 2021 | 28,873.40 |
| Jun 30, 2021 | 36,709.30 |
| Dec 31, 2020 | 5,912.53 |
| Jun 30, 2020 | 27,778.04 |
| Dec 31, 2019 | 32,731.58 |
| Jun 30, 2019 | 24,499.72 |
| Dec 31, 2018 | 0.93 |
| Jun 30, 2018 | 693.45 |
| Dec 31, 2017 | 480.65 |
| Jun 30, 2017 | 0.30 |
| Dec 31, 2016 | 347.32 |
| Jun 30, 2016 | 0.37 |